Cargando…
Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study.
Bryostatin 1, a novel antineoplastic agent and protein kinase C (PKC) activator, has been found to induce myalgia (muscle pain) 48 h after administration in clinical trials. This is the dose-limiting toxicity and has restricted the duration of therapy in phase I trials. To investigate the mechanisms...
Autores principales: | Hickman, P. F., Kemp, G. J., Thompson, C. H., Salisbury, A. J., Wade, K., Harris, A. L., Radda, G. K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034030/ https://www.ncbi.nlm.nih.gov/pubmed/7547256 |
Ejemplares similares
-
Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
por: Thompson, C. H., et al.
Publicado: (1996) -
Antineoplastics: Neutropenia: 31 case reports
Publicado: (2020) -
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018) -
Bryostatin analog: improving on Nature's design
por: Boger, Dale
Publicado: (2012) -
Antineoplastic and Immunosuppressive Agents—Part 1
por: Lajtha, L. G.
Publicado: (1975)